| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Jack Birch Unit of Molecular Carcinogenesis, Department of Biology, University of York, York YO10 5YW [B. A. S., J. S.]; and Imperial Cancer Research Fund Cancer Medicine Research Unit, St. Jamess University Hospital, Leeds LS9 7TF [W. J. K., P. H., P. J. S., L. K. T.], United Kingdom
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The excretory pathways of the urinary tract are lined by urothelium.
TCC2
of urothelial cell origin is the sixth most common cause of cancer
deaths of men in the Western world. Prognosis is strongly correlated
with the tumor stage, determined by the extent of local invasion and
spread to nodes and distant sites. Investigation of normal and
malignant urothelial cells provides some evidence that neoplastic cells
usurp normal cell mechanisms to progress. Normal urothelium has an
exceptionally low cell-turnover rate but a high capacity for
regeneration after injury (1
, 2)
. When isolated from the
basement membrane and placed in monoculture, NHU cells become highly
proliferative and migratory (3)
, as in a wound response.
Analysis of integrin expression has shown that NHU cells in culture
show de novo expression of the
5ß1 integrin and
relocalization of the
6ß4 integrin away from
hemidesmosomes (4)
. These phenomena have also been
demonstrated in TCC in vivo (5
, 6) . We,
therefore, proposed to pursue the hypothesis that TCCs use parts of the
urothelial wound healing response in malignant progression.
We have previously shown that manipulation of culture conditions, and particularly of the culture substratum, alters the behavior of both normal and neoplastic urothelial cells. NHU cells, grown on plastic, form a monolayer and fail to stratify, but, when recombined with a de-epithelialized stroma in organ culture, they revert to a stratified, differentiated low-turnover urothelium (7) . By contrast, TCC cell lines show invasive behavior and a degree of response to stromal signaling, which is dependent on the grade of the originating tumor (8) .
These experiments suggest that the interactions between the cell and the extracellular matrix are important in mediating the normal wound response and have a role in modulating tumor behavior. To dissect the molecular response of NHU cells to stromal signaling, we used differential display to identify genes up-regulated when NHU cells were seeded onto a Matrigel matrix, by comparison to autologous cells grown on plastic. In this study, we identified genes that are integral to the response repertoire of normal cells and investigated expression of a novel gene in clinical tumor samples. We show that this approach can detect genes involved in normal tissue homeostasis that are also relevant to the invasive and metastatic phenotype of TCC.
| MATERIALS AND METHODS |
|---|
|
|
|---|
1-cm2
pieces, placed into
HBSS (Ca2+ and Mg2+ free)
supplemented as above and containing 0.1% (w/v) EDTA, and incubated at
4°C overnight to release the urothelium. The isolated urothelium was
either used to initiate NHU cell lines or used to extract RNA.
Cell Culture.
NHU cell lines were established from ureter (n = 3) and renal pelvis (n = 1), and
maintained in keratinocyte serum-free medium, containing bovine
pituitary extract and epidermal growth factor at the manufacturers
recommended concentrations (Life Technologies, Inc., Paisley, United
Kingdom) and 30 ng/ml Cholera toxin (Sigma Chemical Company, Poole,
United Kingdom). These methods have been described in detail elsewhere
(10)
. NHU cell lines were used for these studies between
passages 4 and 8.
Three established human TCC cell lines were used, comprising RT4, RT112, and EJ. These well-characterized cell lines show a range of phenotypes reflecting the urothelial origin and the different grades of cancer from which the lines were derived (11) and have been shown to have different invasive potentials on bladder stroma (8) . For some experiments, the TCC-derived COLO232 cell line was also included. All of the TCC cell lines were maintained in a 1:1 mixture of RPMI 1640 and DMEM with 5% fetal bovine serum, as described previously (8) .
Culture of NHU Cells on Matrigel.
Matrigel (Becton Dickinson, supplied by Stratech Scientific, Luton,
United Kingdom) was thawed on ice to coat tissue culture dishes
at 100 µl/cm2
and was polymerized at 37°C for
30 min. NHU cells were seeded onto Matrigel at an equivalent density of
5 x 104 to 1 x 105 cells/cm2
and left for
1 h to attach before flooding with growth medium. Parallel
cultures were seeded at equivalent densities onto plastic tissue
culture dishes. Cultures were harvested for RNA extraction at 24- and
48-h time points.
Extraction of RNA.
Isolated sheets of urothelium were homogenized in Ultraspec, and total
RNA was extracted following the manufacturers protocol (Biogenesis,
Bournemouth, United Kingdom).
To extract RNA from Matrigel and control cell cultures, the growth media were aspirated and replaced with 8 ml of Ultraspec. Scrapers were used to detach the cells, and the suspensions were transferred to polypropylene centrifuge tubes. Total RNA was extracted following the manufacturers protocol. At this stage, impurities from the Matrigel were still present, and it was found necessary to precipitate the RNA in 4 M lithium chloride, followed by additional ethanol precipitation and washes (12) . The RNA from cells grown on plastic was treated in exactly the same way. DNA contamination was removed by treatment with a Message Clean kit (GenHunter Corporation, Nashville, TN) according to the manufacturers protocol. All of the RNA preparations were assessed for quality on formaldehyde agarose gels and by A260:A280 ratios.
RNA isolated from human brain, kidney, heart, liver, and lung tissues was obtained from Clontech Laboratories UK Ltd. (Basingstoke, United Kingdom).
ddRT-PCR.
Differential display was performed with three one-base anchored
oligodeoxythymidylate ("downstream") and 10 arbitrary
13-bp ("upstream") primers (see Table 1
), as described previously (13)
. For each cDNA reaction,
200 ng of total RNA was heated to 65°C for 10 min with 50 pmol of
HT11X (where H is a HindIII
site and X is nucleotide A, C, or G), cooled on ice and subsequently
reverse-transcribed in a 20-µl reaction containing 1 x GeneAmp PCR buffer (Perkin-Elmer, Warrington, United Kingdom),
8 mM MgCl2 (Perkin-Elmer),
20 µM each deoxynucleotide triphosphates
(Pharmacia Biotech, St. Albans, United Kingdom) and 5 units of M-MuLV
reverse transcriptase (Pharmacia Biotech) at 37°C for 60 min. Control
reactions were included from which the reverse transcriptase was
omitted. The reverse transcriptase was inactivated by heating at 95°C
for 10 min. PCR amplification of 2 µl of each of the three
first-strand cDNAs was performed in a 20-µl reaction volume
containing 1x GeneAmp PCR buffer [1.5 mM
MgCl2, 20 µM dNTPs, 1
µCi [32P]dATP (Amersham Pharmacia Biotech UK
Ltd, Little Chalfont, United Kingdom)] and 1.25 units of AmpliTaq DNA
polymerase (Perkin-Elmer). The corresponding
HT11X primer and a single upstream primer were
added to final concentrations of 2.5 µM each.
PCR cycling conditions were 95°C for 2 min, followed by 40 cycles at
95°C for 30 s, 32°C for 2 min, and 72°C for 30 s, with
a final incubation at 72°C for 5 min. Separation of the multiple PCR
products was performed on 6% denaturing polyacrylamide gels. Gels were
dried, marked with phosphorescent tape, and exposed overnight to X-ray
film. Alignment of the X-ray film with the gel allowed each band of
interest to be cut out with a clean scalpel and eluted by placing in
100 µl of TE [10 mM Tris, 1
mM EDTA (pH 8.0)] at 65°C overnight.
|
Cloning and Sequencing of PCR Products.
Reamplified PCR products were separated on 1% agarose gels, excised,
and purified using ß-Agarase 1 (BioLabs, Beverly, MA) according to
the manufacturers instructions. Approximately one-half of each
product was TA-cloned into the SmaI site of pGEM 3Z
vector. Up to 10 clones generated from each band were purified using a
Plasmid Mini kit (Quiagen Ltd, Crawley, United Kingdom). Ten µl of
each DNA was digested with HinDIII followed by analysis on
2% agarose gels to estimate insert sizes. When all of the inserts from
one ligation were the same size, initially two clones were sequenced.
When more than one insert size could be seen, clones representing the
alternative products were sequenced. Sequencing reactions were carried
out by BigDye Terminator Cycle Sequencing (Perkin-Elmer, Warrington,
United Kingdom) and the products were analyzed on an ABI Prism 377 DNA
sequencer (ABI, Warrington, United Kingdom). Sequence homologies were
determined by BLAST searches against DNA and EST databases.
RPAs.
32P-antisense transcripts of the cDNAs of
interest were generated from linearized plasmids using an in
vitro transcription kit (Promega, Southampton, United Kingdom),
according to the manufacturers protocol. After DNase treatment,
riboprobes were purified either by phenol-chloroform extraction or by
passage through Chromaspin 30-DEPC columns (Clontech).
A 152-bp portion of the coding region of human GAPDH (accession no. M33197) cloned into pGEM-T Easy (Promega) was used as an internal riboprobe control (14) . Approximately 2 fmol of each test and GAPDH control probe were mixed and hybridized to 5 µg of total RNA (test or yeast control) using an RPAII kit [Ambion; supplied by AMS Biotechnology (Europe) Ltd., Abingdon, United Kingdom], according to the manufacturers protocols. Products were separated on 5% denaturing polyacrylamide gels (Sequagel; Flowgen, Lichfield, United Kingdom) and visualized either by autoradiography or analyzed by means of a phosphorimager (Bio-Rad GS-525 Molecular Imager System; Hemel Hempstead, United Kingdom).
Urothelial cDNA Library Screening.
EST sequences were obtained as I.M.A.G.E. Consortium [LLNL] cDNA
clones (Ref. 14a
) from the United Kingdom Human Genome
Mapping Project Resource Center, Cambridge, and DNA prepared
from the clones was sequenced to confirm that they contained the
expected sequences. The inserts were prepared by digestion with
restriction enzymes EcoRI and NotI, followed by
gel electrophoresis and purification using a Qiagen Gel Extraction kit
(Qiagen). Radioactive probes were prepared from 25 ng of insert
by incorporating [32P]dCTP using the Rediprime
kit (Amersham) according to the manufacturers instructions. Each
probe was used to screen a human urothelial cDNA library cloned in
pCDM8 (14)
.
The library was grown on 15-cm plates at a density of
5 x 104 colonies per plate. Colonies were
lifted onto Hybond N+ membranes (Amersham) followed by denaturation and
fixing according to the manufacturers protocols. The membranes were
prehybridized for 1 h at 65°C in 10 ml of Rapid-hyb buffer
(Amersham), followed by the addition of probe and hybridization for
2.5 h. Posthybridization washes were carried out according to
Amersham protocols. Colonies identified as positive by autoradiography
were scraped into broth, plated at a lower density, and subjected to a
second round of screening. Isolated, single positive colonies were
amplified and sequenced on an ABI 377 automated sequencer.
Northern Blot.
Aliquots (15 µg) of RNA were electrophoresed on a 1.3% (w/v)
agarose/formaldehyde gel and blotted onto Hybond N membrane
(Amersham). 32P-probe was prepared using
the Rediprime II random prime labeling system (Amersham), according to
the manufacturers instructions. Ten % (107
cpm) of the prepared probe were hybridized to the blot in
ULTRAhyb buffer (Ambion), according to the manufacturers instructions
and the hybridization signal visualized by autoradiography.
RNA Dot Blot Hybridization.
A human RNA master blot containing normalized loading of
poly(A) + RNA from 50 different tissues was obtained
from Clontech. Radioactive probe was prepared by incorporating
[32P]dCTP into 25 ng of gel-purified plasmid
insert cDNA using the Rediprime II kit (Amersham) according to the
manufacturers instructions. Unincorporated nucleotides were removed
by applying the probe to a Chromaspin100-TE column (Clontech). The RNA
blot was prehybridized for 2 h at 65°C, hybridized overnight and
washed using the recommended protocol (Clontech). The membranes were
subjected to autoradiography and the density quantified on a
phosphorimager (as above).
In Situ Hybridization.
In situ hybridization on paraffin wax-embedded sections
using 35S-labeled UTP-riboprobes was performed
essentially as detailed previously (14)
. Briefly, 500 ng
of linearized template was used to transcribe a
35S-antisense riboprobe using an in
vitro transcription kit (T7 Riboprobe System from Promega) and
2 x 106 cpm were hybridized
against dewaxed, proteinase K-treated, and acetylated sections. After
removal of nonbound probe, slides were dehydrated, coated in
autoradiographic emulsion, and left for up to 20 days before
development. A ß-actin riboprobe was used to determine RNA transcript
integrity within each tissue.
| RESULTS |
|---|
|
|
|---|
|
Up to six clones from each band or multiplet were sequenced and compared for homogeneity. The majority of bands produced clones that contained a single sequence. Clones from three bands were heterogeneous: two bands were each represented by two independent transcribed sequences, and two bands were contaminated by sequences derived from genomic DNA. Analysis of the resultant clones for homology on the GenBank database showed them to represent 14 independent cDNA sequences. The apparent discrepancy of numbers was attributable to six genes being differentially amplified by more than one primer combination. For example, sequences homologous to Cystatin B were generated from four primer combinations using two upstream primers and either the A- or G-anchored dT11 primer. In each case the anchored primer had primed close to the poly(A) tail, but the upstream priming had occurred in different positions, giving overlapping sequences of between 150 and 330 bp. Similarly, an unknown sequence that matched EST AA459897 was isolated from three different primer combinations.
Confirmation of Differential Gene Expression.
Five of the 14 independent sequences matched known genes. These were
connexin 26, calprotectin (also known as
macrophage migration inhibition factor, MRP-14,
L1, or calgranulin A), cystatin B,
elafin, and antileukoprotease. The other four
clones showed homologies to sequences with unknown functions in human
cells. Clone A20a showed homology to transcript ch138 previously
isolated by differential display from stomach cancer cell lines
(accession no. S77393). No function has been described for this
transcript and a BLAST search on the GenBank database of HTGSs
assigned it to a contig on chromosome 4 (accession no. AC021860). Clone
C1a showed homology to a hypoxia-inducible gene (HIG1;
accession no. AF145385) isolated from cervical cancer cells. Screening
of the HTGS database showed homology to contigs on several chromosomes.
Clone C9c6 showed homology to several EST clones that have been
assigned to a contig (AC024502) on chromosome 9. These EST clones show
homology to the adipophilin gene, and it is possible that our sequence
lies within the 3' untranslated region of adipophilin. Clone C4a2
showed good homology to the 3' end of a rat GPI-anchored
protein associated with metastasis (Ref. 15
; Fig. 2B
).
|
|
EST AA459897, corresponding to IMAGE clone 809414, which showed identity at its 5' end to clone C4a2, identified three positive clones after two rounds of screening. Sequencing showed that two of the clones were virtually identical but that the third had an insert of 300 bases toward the 5' end that probably represented an unspliced intron, because it had consensus donor and acceptor sites at its ends. The full consensus sequence of this Matrigel-induced gene, MIG-C4, was submitted to GenBank (accession no. AF082889).
Analysis of the cDNA sequence of MIG-C4 showed it to be
1690-bp long excluding the poly(A) tail, with an open reading frame
between bases 86 and 1123. This would produce a 346-amino acid sequence
(calculated molecular weight of 35,971), with a
polyadenylation signal sequence at base 1663, a hydrophobic COOH
terminus, and six possible glycosylation sites. Signature analysis of
the amino acid sequence revealed two tandem copies of the Ly-6 cysteine
loop domain, the first of which lacked the fourth disulfide bond (Fig. 2)
.
A BLAST search against GenBank databases found homology with the
previously described rat metastasis-associated GPI-anchored protein
C4.4A (15)
. The homology was 85% at the nucleotide level,
with 72% identity and 78% similarity at the amino acid level (Fig. 2)
.
Expression of the MIG-C4 Gene by Cells and Tissues.
A 774-bp PstI-KpnI fragment of the full length
urothelial MIG-C4 cDNA clone was subcloned into the
equivalent sites in pGEM3Z, which facilitated production of
a 588-bp riboprobe after linearization of the construct using the
internal AccI site. This riboprobe was used in RPA and
confirmed the original analysis of expression using clone C4a2, namely
that the gene was expressed in NHU, RT4, and RT112 cells; up-regulated
in NHU cells on Matrigel; and absent from EJ cells (Fig. 4A)
. This was confirmed by Northern hybridization of the
774-bp fragment of MIG-C4 cDNA. The transcript ran at a
position close to 18S rRNA, which would agree with its estimated size
of 1700-bp minus the poly(A) tail (Fig. 4B)
.
|
|
|
In four cases of invasive TCC with local (n = 1) or distant (n = 3) lymph node metastases,
the MIG-C4 riboprobe showed a positive, tumor-specific
reaction in both the primary and metastatic deposit (Fig. 6)
. The
intensity was consistent between the primary tumor and metastatic
deposits, and ranged from weak to strong intensity. In one of the
cases, in which there was a concurrent prostatic adenocarcinoma, the
MIG-C4 riboprobe hybridized only against the TCC component.
Two additional primary/metastatic tumor pairs did not provide
interpretable results because of a high nonspecific background.
| DISCUSSION |
|---|
|
|
|---|
The protein coded for by the MIG-C4 gene has a hydrophobic COOH terminus common to GPI-anchored proteins (16) . Analysis of the amino acid sequence revealed two conserved signature domains: an 85 amino acid domain distinct from the extracellular portion of the transforming growth factor ß receptor and a 100-amino acid region containing two tandem copies of a cysteine loop domain. This latter identifies the protein as a member of the Ly-6 family of GPI-linked cell surface glycoproteins (17) . The absence of the fourth disulfide bond from the first of the two cysteine loop domains is characteristic of the human uPAR, which is itself a member of the Ly-6 family. However, unlike the MIG-C4 protein, uPAR has three, not two, tandem copies of the cysteine loop domain (18) .
The identified signature domains support a role for MIG-C4 in cell-matrix interactions, and the variable expression of MIG-C4 in sections of normal urothelium supports the likelihood that expression of the gene is inducible in vivo. The massively increased expression of the gene seen in the majority of primary and metastatic TCCs cannot alone be taken to imply a direct causal association between overexpression and TCC progression, because it may simply reflect the presence of a high concentration of inducing factor. Nevertheless, it may provide a valuable disease marker. Indirect evidence for a causal link in tumor progression can be found from studies with the homologous rat C4.4A gene, which encodes a GPI-anchored protein of 352 amino acids (15) . C4.4A expression in rat pancreatic carcinoma cells was associated with enhanced migration through Matrigel and decreased encapsulation of metastases in rats (15) .
In quiescent urothelium in situ, connexin 26, calprotectin, and elafin transcripts were absent, and the other genes identified by ddRT-PCR were detectable only at a low level. This suggests that our strategy has identified genes that constitute part of the repertoire of inducible wound response genes in urothelium. Of the identified genes, only connexin 26 has previously been reported to be expressed by urothelium (19) . Nevertheless, several of the identified genes have recognized roles in cell-cell and cell-matrix interactions, including connexin 26, cystatin B, and elafin.
Interactions between epithelial cells and the stroma during wound repair are highly coordinated processes resulting in tissue remodeling and epithelial restitution. We suggest that malignant cells use the same mechanisms as normal cells to remodel the stromal matrix but lack some of the normal feedback constraints. Thus, identification of gene expression changes associated with normal urothelial cell-matrix interactions may reveal the mechanisms of TCC tumor invasion and/or provide markers of tumor progression. In addition to the possible role of MIG-C4/C4.4A in tumor spread discussed above, several other of the genes identified as differentially up-regulated by NHU cells on Matrigel have been implicated as invasion or metastasis suppressor genes in carcinomas. This includes connexin 26, loss of which has been reported in invasive TCC tumors and cell lines (19 , 20) . Cystatin B is a cysteine-proteinase inhibitor, which mainly inhibits cathepsin L. The expression of cystatin B is markedly decreased in esophageal carcinomas, and this loss has been associated with advanced stage and lymph node metastasis (21) . By contrast, increased activity of cathepsin L has been reported in a number of human carcinomas (22, 23, 24, 25, 26, 27) . Elafin is an inhibitor of elastase and is also known as skin-derived antileukoproteinase (SKALP). Elafin is not expressed by normal epidermis but is expressed by keratinocytes under hyperproliferative conditions, such as wound healing, psoriasis, and in cell culture. The role of elafin may be to prevent proteolytic degradation of elastic tissues during tissue remodeling (28) , and loss of elafin expression has been associated with carcinomas of skin and breast (29 , 30) , which suggests a possible role in tumor spread. One study has shown elastase activity in human bladder cancer cell lines derived from high-grade invasive tumors (31) .
In conclusion, we have identified previously nonimplicated gene products involved in normal urothelium-matrix interactions that could be tumor invasion or suppressor gene targets in the development of invasive and metastatic tumor phenotypes. Furthermore, the identification of cystatin B (a cysteine protease inhibitor) and the serine proteinase inhibitors, elafin and antileukoprotease, raises the possibility that this approach may be useful in identifying novel protease inhibitors.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
1 To whom requests for reprints should be
addressed, at Jack Birch Unit of Molecular Carcinogenesis, Department
of Biology, University of York, York YO10 5YW, United Kingdom. Phone:
44-0-190-443-2902; Fax: 44-0-190-442-3954; E-mail: js35{at}york.ac.uk ![]()
2 The abbreviations used are: TCC, transitional
cell carcinoma; NHU, normal human urothelial; EST, expressed sequence
tag; RPA, RNase protection assay; ddRT-PCR, differential display
reverse transcription-PCR; poly(A), polyadenylic acid; HTGS,
high-throughput genome sequence; uPAR, urokinase plasminogen activator
receptor. ![]()
Received 6/ 5/00. Accepted 12/13/00.
| REFERENCES |
|---|
|
|
|---|
6ß4 integrin and collagen VII in bladder cancer.. Am. J. Pathol., 144: 787-795, 1994.[Abstract]
5 expression and the malignant phenotype of transitional cell carcinoma.. Br. J. Cancer, 73: 327-331, 1996.[Medline]
-neurotoxins. FEBS Lett., 349: 163-168, 1994.[Medline]
This article has been cited by other articles:
![]() |
C. L. Varley, J. Stahlschmidt, B. Smith, M. Stower, and J. Southgate Activation of Peroxisome Proliferator-Activated Receptor-{gamma} Reverses Squamous Metaplasia and Induces Transitional Differentiation in Normal Human Urothelial Cells Am. J. Pathol., May 1, 2004; 164(5): 1789 - 1798. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Stronach, G. C. Sellar, C. Blenkiron, G. J. Rabiasz, K. J. Taylor, E. P. Miller, C. E. Massie, A. Al-Nafussi, J. F. Smyth, D. J. Porteous, et al. Identification of Clinically Relevant Genes on Chromosome 11 in a Functional Model of Ovarian Cancer Tumor Suppression Cancer Res., December 15, 2003; 63(24): 8648 - 8655. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Diggle, S. Cruickshank, J. D. Olsburgh, S. Pellegrin, B. Smith, R. E. Banks, P. J. Selby, M. A. Knowles, J. Southgate, and P. Harnden Identification of Genes Up-Regulated in Urothelial Tumors: The 67-kd Laminin Receptor and Tumor-Associated Trypsin Inhibitor Am. J. Pathol., August 1, 2003; 163(2): 493 - 504. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |